EyePoint Pharmaceuticals, Inc.
EYPT
NASDAQ·Healthcare·Biotechnology·Mkt cap $384.0M
$4.58
▲ +0.33%
P/E
-1.22
Mkt Cap
$384.0M
52-Wk Range
$3.95–$19.11
52-Week Range
$3.95 - $19.11
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 66.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Sustained-release pharmaceutical technology
- Specialized ophthalmology focus
- Diverse clinical-stage product pipeline
- Strategic pharmaceutical partnerships
Bear Case
1 risk
- Above-average volatility (beta 1.6).
Growth
Revenue decline expected
Aging global population
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Falling
-60.0% over 3m
Quality
Strong
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying EYPT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 5, 2026
Reported EPS of -$1.09 vs -$0.96 consensus (-13.9% surprise). Revenue of $507.0K vs $451.2K expected (+12.4%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-13.9%
Revenue trend · last 8Q
—
-17%
+109%
-44%
-91%
-95%
-97%
-90%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$10.5M
$11.6M
$24.5M
$5.3M
$966.0K
$620.0K
$696.0K
$507.0K
Margins · last 8Q
Gross
0.0%
Operating
—
Profit
-18633.1%
Wall Street consensus
3 analysts · 67% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
67%
Hold
33%
Sell
0%
Median Price Target
—
Latest: TD Cowen · Sep 2, 2026
vs Industry
How EYPT stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related